Market Closed - Nasdaq 04:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
7.41 USD +7.86% Intraday chart for NeuroPace, Inc. +2.35% -28.13%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell Small Cap Completeness Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 2000 Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 3000E Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 2500 Growth Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 3000E Growth Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 3000 Growth Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 2000 Growth Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 2000 Dynamic Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell Small Cap Comp Growth Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 2500 Index CI
NeuroPace, Inc.(NasdaqGM:NPCE) added to Russell 3000 Index CI
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating MT
NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : NeuroPace, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M MT
NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024 CI
North American Morning Briefing : Inflation -2- DJ
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16 MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating MT
NeuroPace Shares Decline Following Q4 Financial Results MT
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NeuroPace, Inc., Q4 2023 Earnings Call, Mar 05, 2024
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M MT
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024 CI
Chart NeuroPace, Inc.
More charts
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.41 USD
Average target price
17.21 USD
Spread / Average Target
+132.31%
Consensus
  1. Stock Market
  2. Equities
  3. NPCE Stock
  4. News NeuroPace, Inc.
  5. Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16